All Updates

All Updates

icon
Filter
Funding
MiroBio raises USD 97 million in Series B funding round
Precision Medicine
Jun 29, 2022
This week:
Partnerships
Intuitive AI partner with Moda Center to implement Oscar Sort recycling technology
Waste Recovery & Management Tech
Yesterday
Management news
Funding
Minze Health raises USD 5.3 million in funding for product and market expansion; appoints new VP
Preventive Healthcare
Yesterday
Partnerships
Firefly Aerospace partners with True Anomaly for Space Force rapid-response mission launches
Space Travel and Exploration Tech
Yesterday
Funding
zkPass raises USD 12.5 million in Series A funding
Enterprise Blockchain Solutions
Yesterday
Partnerships
Ontada partners with Microsoft to process unstructured oncology data using Azure AI
Clinical Trial Technology
Yesterday
Product updates
Burcon unveils canola protein isolate for egg replacement
Plant-based Dairy & Egg
Yesterday
Product updates
Bene Meat Technologies produces first cultivated burger at parity with premium beef
Cell-cultured Meat
Yesterday
Geographic expansion
Regulation/policy
The Better Meat Co. expands to Asia with Singapore approval for Rhiza mycoprotein
Plant-based Meat
Yesterday
Listing
Pony.ai files for US IPO
Auto Tech
Yesterday
Product updates
MineOS launches DSR management 2.0
Digital Privacy Tools
Yesterday
Precision Medicine

Precision Medicine

Jun 29, 2022

MiroBio raises USD 97 million in Series B funding round

Funding

  • UK-based clinical-stage biotechnology startup MiroBio has raised USD 97 million (GBP 80 million) in a Series B funding round led by Medicxi, with participation from several other new and existing investors including OrbiMed. Nick Williams of Medicxi and Erez Chimovits of OrbiMed will join MiroBio’s board of directors.

  • The funds will be used to progress its lead antibody drug candidates, MB272 and MB151 into clinical trials. The MB272 and MB151 candidates are checkpoint receptor agonists for treating autoimmune diseases. The funds will also be directed toward advancing its preclinical pipeline and building out its proprietary I-ReSToRE (REceptor Selection and Targeting to Reinstate immune Equilibrium) discovery platform.

  • MiroBio’s I-ReSToRE platform was designed to help discover and develop treatment strategies for autoimmune diseases, based on an atlas of receptor expressions and functions, antibody discovery processes, and advanced bioinformatics. The firm’s technology was built on more than 15 years of checkpoint agonism research at the University of Oxford.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.